Research programme: peptide therapeutics - Susavion Biosciences

Drug Profile

Research programme: peptide therapeutics - Susavion Biosciences

Alternative Names: sv 6B; sv 6D; svC 2; svH 1C; svH 1D; svL 4

Latest Information Update: 15 Jul 2015

Price : $50

At a glance

  • Originator Susavion Biosciences
  • Developer California Department of Health Services; Susavion Biosciences; University of Patras
  • Class Antineoplastics; Antivirals; Peptides
  • Mechanism of Action Lectin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Viral infections

Most Recent Events

  • 29 Jun 2015 Preclinical trials in Viral infections in USA (unspecified route)
  • 29 Jun 2015 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top